Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14631737 | 0.86 | HTR6 (0.53) | HTR6POLBL3MBTL1HDAC1HDAC6 | |
| SCHEMBL30075056 | 0.86 | HTR6 (0.53) | HTR6POLBL3MBTL1HDAC1HDAC6 | |
| SCHEMBL28037053 | 0.83 | HTR6 (0.63) | HTR6POLBL3MBTL1HDAC1HDAC6 | |
| SCHEMBL947751 | 0.82 | HTR6 (0.63) | HTR6POLBL3MBTL1MEN1ALDH1A1 | |
| SCHEMBL948701 | 0.81 | HTR6 (0.58) | HTR6POLBL3MBTL1HDAC1HDAC6 | |
| SCHEMBL947644 | 0.79 | HTR6 (0.72) | HTR6POLBL3MBTL1HDAC1HDAC6 | |
| SCHEMBL1444485 | 0.78 | PPARG (0.40) | HTR6 | |
| SCHEMBL28685370 | 0.78 | HTR6 (0.56) | HTR6POLBL3MBTL1HDAC1HDAC6 | |
| SCHEMBL1444197 | 0.77 | HTR6 (0.61) | HTR6POLBL3MBTL1MEN1ALDH1A1 | |
| SCHEMBL12096981 | 0.75 | PPARG (0.57) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | HTR6 129/4885POLB 2609/4885L3MBTL1 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.